

Davillas, Apostolos; Jones, Andrew M.

Working Paper

Parametric models for biomarkers based on flexible size distributions

ISER Working Paper Series, No. 2018-03

Provided in Cooperation with:

Institute for Social and Economic Research (ISER), University of Essex

Suggested Citation: Davillas, Apostolos; Jones, Andrew M. (2018) : Parametric models for biomarkers based on flexible size distributions, ISER Working Paper Series, No. 2018-03, University of Essex, Institute for Social and Economic Research (ISER), Colchester

This Version is available at:

<https://hdl.handle.net/10419/200367>

Standard-Nutzungsbedingungen:

Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.

Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.

Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte.

Terms of use:

Documents in EconStor may be saved and copied for your personal and scholarly purposes.

You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.

If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.

Parametric Models for Biomarkers Based on Flexible Size Distributions

Apostolos Davillas

Institute for Social and Economic Research
University of Essex

Andrew M Jones

Department of Economics and Related Studies
University of York
Centre for Health Economics
Monash University

No. 2018-03
March 2018



INSTITUTE FOR SOCIAL
& ECONOMIC RESEARCH

Non-Technical Summary

Recent developments in social surveys include the integration of biomarkers and self-reported health measures. Unlike self-reported health, biomarkers are more objective health measures, provide information on pre-disease conditions and insights on the biological links between socio-economic status and health. Hence, biomarkers became popular to a growing number of economic studies, stressing the need for appropriate regression methods. However, biomarker data impose a number of statistical challenges, often being distributed asymmetrically with heavy tails.

Existing studies have applied conventional least squares methods (OLS) on raw or log transformed biomarkers and alternative inherently nonlinear specifications, such as the generalized linear models (GLM), to model biomarker data. While using log rather than linear OLS might improve performance by reducing skewness, re-transformation to the raw scale – as health policymakers require – is highly challenging. Although the GLM family deals with heteroskedasticity, it fails to explicitly account for skewness and kurtosis, imposing potential bias and efficiency losses.

Our paper contributes to the literature by comparing the performance of a set of more flexible parametric distributions for modelling biomarkers; the generalized beta of the second kind (GB2), the generalized gamma (GG) and their nine nested and limiting cases. We use nationally representative UK data (Understanding Society: the UK Household Longitudinal Study) and we focus on commonly used blood-based biomarkers of inflammation (fibrinogen), diabetes (HbA1c), cholesterol and stress-related hormones.

We find that although some of the models nested within the GB2 distribution outperform the latter for most of the biomarkers considered, the GB2 can be used as a guide for choosing among competing parametric distributions. Given that different biomarkers exhibit different distributions, identifying GB2 as a discriminatory tool amongst competing distributions for modelling biomarkers is a useful message for the applied health researchers. Going “beyond the mean”, we also explore the ability of these models to predict tail probabilities; prediction bias at the tails of the biomarkers distribution is of policy interest because of the elevated health risks and associated health-care costs. We find that GB2 performs fairly well with some disparities at the very high levels of HbA1c and fibrinogen. Commonly used OLS models are shown to perform worse than almost all the flexible distributions.

Parametric models for biomarkers based on flexible size distributions

Apostolos Davillas

Institute for Social and Economic Research, University of Essex

Andrew M Jones

Department of Economics and Related Studies, University of York

Centre for Health Economics, Monash University

Abstract

Recent advances in social science surveys include collection of biological samples. Although biomarkers offer a large potential for social science and economic research, they impose a number of statistical challenges, often being distributed asymmetrically with heavy tails. Using data from the UK Household Panel Survey (UKHLS), we illustrate the comparative performance of a set of flexible parametric distributions, which allow for a wide range of skewness and kurtosis: the four-parameter generalized beta of the second kind (GB2), the three-parameter generalized gamma (GG) and their three-, two- or one-parameter nested and limiting cases. Commonly used blood-based biomarkers for inflammation, diabetes, cholesterol and stress-related hormones are modelled. Although some of the three-parameter distributions nested within the GB2 outperform the latter for most of the biomarkers considered, the GB2 can be used as a guide for choosing among competing parametric distributions for biomarkers. Going “beyond the mean” to estimate tail probabilities, we find that GB2 performs fairly well with some disparities at the very high levels of HbA1c and fibrinogen. Commonly used OLS models are shown to perform worse than almost all the flexible distributions.

Keywords: biomarkers; generalised beta of second kind, heavy tails, tail probabilities

JEL codes: C18, C52, I14.

Corresponding author: Apostolos Davillas; Institute for Social and Economic Research, University of Essex, Wivenhoe Park, Colchester, Essex, CO4 3SQ, UK; adavil@essex.ac.uk

Understanding Society is an initiative funded by the Economic and Social Research Council and various Government Departments, with scientific leadership by the Institute for Social and Economic Research, University of Essex, and survey delivery by NatCen Social Research and Kantar Public. The research data are distributed by the UK Data Service. We are grateful to the Economic and Social Research Council for financial support for this research via project “How can biomarkers and genetics improve our understanding of society and health?” (award no. ES/M008592/1). Andrew Jones acknowledges funding from the Leverhulme Trust Major Research Fellowship (MRF-2016-004). The funders, data creators and UK Data Service have no responsibility for the contents of this paper.

1. Introduction

Recent developments in social surveys include the integration of biomarkers and self-reported health measures. Biomarkers are objectively measured indicators of normal biological or pathogenic processes and, as such, offer at least two key advances over self-report health. First, biomarkers are not subject to reporting bias; given evidence for socioeconomic-related reporting bias in health, biomarkers offer a significant advantage in socioeconomic inequalities research (Bago d’Uva et al., 2008; Carrieri and Jones, 2014). Second, biomarkers can contribute to our understanding of the underlying biological factors through which socioeconomic conditions get “under the skin” (for example, thought stress-related physiological responses) as well as the role of socioeconomic exposures at earlier pre-symptomatic health states (Davillas et al., 2016; Gruenewald et al., 2009; Jürges et al., 2013).

A growing number of studies analyse the effect of socioeconomic position on the conditional mean of biomarkers (e.g., Davillas et al., 2016, Gruenewald et al., 2009, Jürges et al., 2013). However, biomarkers create several statistical modelling challenges as they often have skewed distributions with heavy tails (Jones, 2017). Furthermore, errors are likely to be heteroskedastic and responses to covariates may be nonlinear. Existing studies have applied OLS on raw or log transformed biomarkers (Gruenewald et al., 2009; Jürges et al., 2013) and alternative inherently nonlinear specifications, such as the generalized linear models (GLM) (Davillas et al., 2016). While using log rather than linear OLS might improve performance by reducing skewness, re-transformation to the raw scale—as health policymakers require—is highly challenging, requiring knowledge of the degree and form of heteroscedasticity (Jones et al., 2014). Although the GLM family deals with heteroskedasticity, it fails to explicitly account for skewness and kurtosis, imposing potential bias and efficiency losses (Jones et al., 2014).

Our paper contributes to the literature on modelling biomarkers by comparing the performance of a set of more flexible parametric distributions, the generalized beta of the second kind (GB2), the generalized gamma (GG) and their nine nested and limiting cases; we use nationally representative UK data on commonly used blood-based biomarkers for inflammation, diabetes, cholesterol and stress-related hormones (Carrieri and Jones,

2016). The GG and GB2 allow for a wide range of skewness and kurtosis to better accommodate the biomarker data generation processes; these models have been proposed for fitting heavily skewed outcomes (for example, health care costs; Jones et al., 2014), to which biomarkers share similar distributional features. OLS models are also estimated for comparison purposes. Given that different biomarkers exhibit different distributions, identifying GB2 as a discriminatory tool amongst competing distributions might be useful for health researchers. Going “beyond the mean”, we also explore the ability of these models to predict tail probabilities; prediction bias at the tails are of policy interest because of the elevated health risks and associated health-care costs.

2. Methods

The three-parameter GG distribution has a density function and conditional expectation that take the form:

$$f(y; \kappa, \mu, \sigma) = \frac{\gamma^\gamma}{\sigma y \sqrt{\gamma} \Gamma(\gamma)} \exp(z\sqrt{\gamma} - u) \quad (1)$$

and

$$E(y|x) = \exp(x'\beta) \left[k^{2\sigma/\kappa} \frac{\Gamma(\frac{1}{\kappa^2} + \frac{\sigma}{\kappa})}{\Gamma(\frac{1}{\kappa^2})} \right] \quad (2)$$

where, $\gamma = |\kappa|^{-2}$, $z = \text{sign}(\kappa)\{\ln(y) - \mu\}$, $u = \gamma \exp(|\kappa|z)$, $\mu = x'\beta$ and $\Gamma(\cdot)$ is the gamma function. Parameters κ and σ are the shape parameters (Manning et al., 2005). The GG nests the gamma ($\kappa = \sigma$), Weibull ($\kappa = 1$), exponential ($\kappa = 1, \sigma = 1$), and lognormal ($\kappa = 0$) distributions.

The 4-parameter GB2 model adds further flexibility and has a mean of:

$$E(y) = b \left[\frac{\Gamma(p + \frac{1}{a}) \Gamma(q - \frac{1}{a})}{\Gamma(p) \Gamma(q)} \right] \quad (3)$$

where, $b = \exp(x'\beta)$ and $\Gamma(\cdot)$ is the gamma function (Jones et al., 2014). Parameter a influences kurtosis and p and q the skewness of the distribution. We also estimate the nested and limiting cases of GB2; the three-parameter Beta of the second kind (B2) [$a = 1$], Singh-Maddala (SM) [$p = 1$] and Dagum [$q = 1$]; the two-parameter Fisk [$p = q = 1$], and Lomax [$p = a = 1$]. GG itself is also a limiting case of the GB2. We also estimate OLS models for comparison purposes.

The restrictions imposed by each of the special and limiting cases within the GG and GB2 are evaluated using Wald and likelihood-ratio (LR) tests. To assess the comparative performance of beta- with gamma-family models (being limited, non-nested cases), we use Akaike (AIC) and Bayesian (BIC) information criteria (Jones et al., 2014).

3. Data

The UK Household Panel Study (UKHLS) is a large, nationally representative UK study. At UKHLS wave 2, participants from its predecessor, the British Household Panel Survey (BHPS), were also incorporated. Non-fasted blood samples were collected, after the UKHLS wave 2 interview for the original UKHLS respondents and, at wave 3, for the BHPS sample (Benzeval et al., 2014). Pooling biomarker data from UKHLS waves 2 and 3 (2010-2013), resulted in a potential sample of 13,107 respondents.

Four biomarkers are used. Fibrinogen is an inflammatory biomarker, with higher values linked to cardiovascular morbidity and all-cause mortality risks (Davillas et al., 2017). Glycated haemoglobin (HbA1c) is a diagnostic biomarker for diabetes (Benzeval et al., 2014). The ratio of total cholesterol to high-density lipoprotein cholesterol (i.e., cholesterol ratio) is used as a marker for fatty substances in the blood.

Dehydroepiandrosterone sulfate (DHEAS) is a common steroid hormone and one of the primary mechanisms through which psychosocial stressors might affect health (Vie et al., 2014). We model biomarkers as a function of polynomials of age (cubic or quartic depending on the biomarker used), gender, and their interactions to allow for flexible gender effects (Figure A1, appendix).

4. Results

Table 1 and Figure 1 present descriptive statistics and the distribution of biomarkers. Fibrinogen has a symmetric distribution but with heaping and fat tails (Figure 1). HbA1c is much more skewed (skewness statistic of 4.2 compared to zero for normal data) with long right-hand tails and excess kurtosis (31.15 versus 3 for normal data). The cholesterol ratio and DHEAS also exhibits long right-hand tails and high kurtosis.

Table 1. Descriptive statistics

Biomarker	Mean	Median	Standard deviation	Skewness	Kurtosis	Sample size
Fibrinogen (g/l)	2.79	2.70	0.59	0.47	3.82	12,811
HbA1c (mmol/mol)	37.25	36.00	8.19	4.17	31.15	12,153
Cholesterol ratio	3.74	3.46	1.36	1.42	6.43	12,865
DHEAS ($\mu\text{mol/l}$)	4.62	3.80	3.24	1.29	5.11	12,809

Table 2 contains restriction tests for the nested and limiting models within the GG and GB2. Across all biomarkers, we find no evidence in support of any of the special cases within the GG distribution. For fibrinogen, we are unable to reject the null hypothesis of the restriction being valid for the SM model. Our results for HbA1c do not support any of the nested distributions. For the cholesterol ratio, both the LR and Wald tests favour the B2 distribution. Although the Wald test also fails to reject the null hypothesis for SM, this is not confirmed by the LR test; this disparity reflects the wide confidence intervals for GB2's p parameter (which include both one, satisfying the SM restriction, but also zero; Table A1, appendix). Our results for DHEAS favour the SM distribution.

Table 2. Likelihood-ratio (LR) and Wald tests (p-values) for special cases of the GB2 and GG distributions.

	<i>Fibrinogen</i>		<i>HbA1c</i>		<i>Cholesterol ratio</i>		<i>DHEAS</i>	
	LR	Wald	LR	Wald	LR	Wald	LR	Wald
<i>GB2 vs...</i>								
B2	0.000	0.000	0.000	0.000	0.247	0.193	0.000	0.000
SM	0.208	0.236	0.000	0.000	0.000	0.188	0.703	0.710
Dagum	0.004	0.013	0.000	0.000	0.000	0.020	0.000	0.000
Fisk	0.002	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Lomax	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
<i>GG vs...</i>								
Gamma	0.000	0.024	0.000	0.000	0.000	0.000	0.000	0.000
Log Normal	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Weibull	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Exponential	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000

Table 3 shows that AIC and BIC results are in accordance with the tests of Table 2. For all biomarkers, OLS performs worse than each of the four- and three-parameter and most of the more parsimonious models. For fibrinogen, GB2 and SM perform best according to AIC and BIC criteria, with the latter showing the best performance. GB2 outperforms all the competing models regarding HbA1c. While the B2 and the SM distribution exhibit the best performance for the Cholesterol ratio and DHEAS, GB2 is ranked the second best.

Figure 2 presents the conditional tail probabilities (at 10th, 25th, 50th, 75th and 90th quantile) and spike plots of the actual-fitted difference (bias) for the GB2 distribution and its nested models exerted the best performance for each biomarker (Table 3). There are limited differences in the predictive ability of the more parsimonious models compared to GB2, confirming previous evidence that a flexible distribution is not a substitute for finding the correct distribution (Manning et al., 2005; Jones et al., 2014). GB2 performs reasonably well at predicting tail probabilities, although there are some disparities at the very high fibrinogen levels (90th quantile) and HbA1c above the pre-diabetes threshold (HbA1c \geq 42 mmol/mol).

Table 3. Values for each model's AIC and BIC.

Distribution	Fibrinogen		Hba1c		Cholesterol ratio		DHEAS	
	AIC	BIC	AIC	BIC	AIC	BIC	AIC	BIC
GB2	20866	20948	72138	72219	39175	39257	53800	53889
B2	21221	21296	76134	76371	39173	39249	53897	53979
SM	20865	20939	72329	72404	39432	39506	53798	53880
Dagum	20872	20947	72927	73001	39315	39390	53855	53937
Fisk	20883	20950	73563	73629	39482	39549	54149	54223
Lomax	51843	51910	112182	112249	59542	59624	61959	62040
GG	21204	21278	74986	75060	39180	39270	53927	54016
Log-normal	21502	21569	77305	77372	39306	39373	54407	54482
Gamma	21219	21287	79049	79116	39867	39934	53942	54016
Weibull	22804	22871	88676	88743	42443	42518	54640	54715
Exponential	51841	51900	112180	112239	59540	59615	61957	62031
OLS	21500	21558	84119	84178	42875	42950	58371	58446

5. Conclusion

Biomarkers have a large potential for social and economic research but they impose statistical challenges. We illustrate the comparative performance of a set of more flexible parametric distributions, the GB2, GG, and their nested and limiting cases for a set of biomarkers. Although some of the three-parameter distributions nested within the GB2 (mainly the B2 and SM) outperform the latter in most of the biomarkers considered, GB2 can be used as a guide for choosing among competing distributions; a potentially useful message for applied researchers given that different biomarkers follow different distributions. However, going “beyond the mean” to estimate tail probabilities we find limited differences in performance of these distributions compared to GB2. The conventional OLS models are dominated by almost all the competitive models. GB2 performs well at predicting biomarkers' tail probabilities, although with some disparities at the very high levels of fibrinogen and HbA1c.

References

Bago d’Uva, T., O’Donnell, O., van Doorslaer, E., 2008. Differential health reporting by education level and its impact on the measurement of health inequalities among older Europeans. *International Journal of Epidemiology*, 37(6), 1375–1383.

Benzeval, M., Davillas, A., Kumari, M., Lynn, P. (2014). *Understanding Society: Biomarker User Guide and Glossary*. Colchester: University of Essex

Carrieri, V., Jones, A.M. (2017). The Income–Health Relationship ‘Beyond the Mean’: New Evidence from Biomarkers. *Health Economics*, 26(7), 937-956.

Davillas, A., Benzeval, M., Kumari, M. (2017). Socio-economic inequalities in C-reactive protein and fibrinogen across the adult age span: Findings from Understanding Society. *Scientific Reports*, 7(1), 2641.

Gruenewald, T. L., Cohen, S., Matthews, K. A., Tracy, R., Seeman, T. (2009). Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Social Science & Medicine*, 69(3), 451-459.

Jones, A.M. (2017). Data visualization and health econometrics, *Foundations and Trends in Econometrics*, 9, 1-78.

Jones, A.M., Lomas, J., Rice, N. (2014). Applying beta-type size distributions to healthcare cost regressions. *Journal of Applied Econometrics* **29**, 649-670.

Jürges, H., Kruk, E., Reinhold, S. (2013). The effect of compulsory schooling on health-evidence from biomarkers. *Journal of Population Economics*, 26(2), 645-672.

Manning, W. G., Basu, A., Mullahy, J. (2005). Generalized modeling approaches to risk adjustment of skewed outcomes data. *Journal of Health Economics*, 24(3), 465-488.

Vie, T., Hufthammer, K. O., Holmen, T. L., Meland, E., Breidablik, H. J. (2014). Is self-rated health a stable and predictive factor for allostatic load in early adulthood? Findings from the Nord Trøndelag Health Study. *Social Science & Medicine*, 117, 1-9.

Figure 1. Distribution of biomarkers and quantile-normal (Q-N) plots






Figure 2. Actual versus fitted tail probabilities.

Fibrinogen

Generalised beta of the second kind (GB2)




Singh-Maddala (SM)




HbA1c

Generalised beta of the second kind (GB2)




Singh-Maddala (SM)




Cholesterol ratio

Generalised beta of the second kind (GB2)




Beta of the second kind (B2)




DHEAS

Generalised beta of the second kind (GB2)



Singh-Maddala (SM)



Appendix

Figure A1. Quantile-quantile plots of the biomarkers by gender




Table A1. Estimated parameters from the generalized beta two (GB2) and the generalized gamma (GG) models.

Biomarker	Generalized beta two (GB2)			Generalized gamma (GG)	
	α	p	q	κ	$\text{Ln}(\sigma)$
Fibrinogen	7.892 [7.017; 8.767]	1.104 [0.933; 1.275]	1.299 [1.063; 1.535]	0.267 [0.209; 0.326]	-1.606 [-1.621; -1.592]
HbA1c	42.986 [36.674; 49.298]	0.348 [0.287; 0.410]	0.198 [0.167; 0.230]	-0.461 [-0.555; -0.368]	-1.970 [-2.017; -1.924]
Cholesterol ratio	1.442 [0.777; 2.108]	23.345 [-9.920; 56.612]	6.611 [1.761; 11.463]	-0.246 [-0.290; -0.200]	-1.169 [-1.183; -1.157]
DHEAS	2.538 [2.202; 2.873]	1.036 [0.846; 1.225]	2.316 [1.717; 2.915]	0.446 [0.396; 0.495]	-0.615 [-0.631; -0.599]